← Search & browse all drugs
GENITO URINARY SYSTEM AND SEX HORMONES › UROLOGICALS › UROLOGICALS › Drugs for urinary frequency and incontinence
darifenacin
G04BD10
Forms & Strengths
- Extended-release tablets: 7.5 mg
- Extended-release tablets: 15 mg
Adult Dosing
- Overactive bladder: Initial 7.5 mg orally once daily
- May increase to 15 mg orally once daily based on efficacy and tolerability
- Maximum dose: 15 mg orally once daily
- Moderate hepatic impairment (Child-Pugh Class B): Maximum 7.5 mg orally once daily
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency
Mechanism of Action
- Competitive muscarinic receptor antagonist with relative selectivity for the M3 receptor subtype
- Inhibition of M3 receptors in the bladder detrusor muscle decreases bladder smooth muscle contractions and urgency
Contraindications
- Urinary retention
- Gastric retention
- Uncontrolled narrow-angle glaucoma
- Known hypersensitivity to darifenacin or any formulation components
Adverse Reactions
- Dry mouth
- Constipation
- Dyspepsia
- Urinary tract infection
- Blurred vision
- Dizziness
- Asthenia
Drug Interactions
- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir): Increase darifenacin exposure; limit dose to 7.5 mg daily
- CYP2D6 substrates (e.g., thioridazine, tricyclic antidepressants): Darifenacin may increase plasma concentrations of co-administered drugs metabolized by CYP2D6
- Other anticholinergic agents (e.g., antispasmodics, antiparkinsonian drugs): May result in additive anticholinergic toxicity and decreased therapeutic efficacy
Curated Content: Needs Vetting Before Put to Clinical Use